Table 1. Clinical characteristics of the no leakage and leakage groups.
| No leakage group (n = 115) | Leakage group (n = 152) | |
|---|---|---|
| Sex, no. female/male | 42/73 | 70/82 |
| Age, year, median (IQR) | 35 (24–47) | 32.5 (25–43.75) |
| BMI, kg/m2, median (IQR) | 24.22 (22.83–27.88) | 24.60 (23.04–26.62) |
| Blood pressure, critical phase | ||
| SBP, mmHg, median (IQR) | 110 (110–120) | 110 (110–120) |
| DBP, mmHg, median (IQR) | 80 (70–80) | 73 (70–80) |
| AST level, febrile phase, U/L, median (IQR) | 41 (27–65) | 49 (33–89.50)a,* |
| ALT level, febrile phase, U/L, median (IQR) | 54 (35–84) | 56 (37–88.75) |
| AST level, critical phase, U/L, median (IQR) | 81 (43–133) | 152.50 (94.25–279.5) a,* |
| ALT level, critical phase, U/L, median (IQR) | 83 (51–133) | 119 (69–218.25) a,* |
| Hemoconcentration, %, median (IQR) | 10.62 (7.71–13.85) | 16.92 (11.25–23.09) a,* |
| Lowest platelet count, × 1,000/μL, median (IQR) | 69 (34–101) | 19 (12–33.75) a,* |
| Albumin level, g/dL, median (IQR) | 3.5 (3.2–3.7) | 3.1 (2.9–3.3) a,* |
| Absence of NAFLD, n (%) | 53 (38.4) | 85 (61.6) |
| Presence of NAFLD, n (%) | 62 (48.1) | 67 (51.9) |
| Severe dengue, n (%) | 0 | 8 (5.26)b,* |
| AST or ALT ≥1000 U/L, n (%) | 0 | 3 (1.97) |
| Shock, n (%) | 0 | 2 (1.31) |
| Respiratory distress, n (%) | 0 | 1 (0.66) |
| Acute kidney injury, n (%) | 0 | 1 (0.66) |
| Multiple organ failure, n (%) | 0 | 1 (0.66) |
| LOS, days, median (IQR) | 5 (4–6) | 6 (5–7) a,* |
Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; AST, aspartate aminotransferase; ALT, alanine aminotransferase; IQR, interquartile range; NAFLD, nonalcoholic fatty liver disease; LOS, length of hospital stay
a The Mann-Whitney test was used to assess differences between the no leakage and leakage groups.
b Fisher’s exact test was used to evaluate associations between the no leakage and leakage groups.
* Significantly different from the no leakage group (p<0.05).